---
figid: PMC5505220__en.2017-00163f3
figlink: /pmc/articles/PMC5505220/figure/F3/
number: F3
caption: Modeled mechanism by which FSH via PKA inhibits MKP3/DUSP6 to promote the
  accumulation of phosphorylated ERK in preantral GCs. Schematic model, based on recent
  publications (, ), reflects the observation that the EGFR pathway is constitutively
  active in the absence of FSH, such that MEK phosphorylation is abrogated by the
  EGFR antagonist AG1478, the Src homology 2–domain-containing tyrosine phosphatase-2
  inhibitor NSC87877, a dominant negative (S17N) RAS, and the MEK inhibitor PD98059.
  FSH promotes an accumulation of phosphorylated ERK, in a PKA-dependent manner, without
  affecting MEK phosphorylation. ERK is dephosphorylated in the absence of FSH by
  MKP3/DUSP6; FSH in a PKA-dependent manner inhibits this phosphatase to allow the
  accumulation of MEK-phosphorylated ERK that then signals to ribosomal S6 kinase-2
  and Y-box-binding protein 1. Dotted line indicates that the mechanism by which PKA
  inhibits MKP3/DUSP6 is not known.
pmcid: PMC5505220
papertitle: How Protein Kinase A Activates Canonical Tyrosine Kinase Signaling Pathways
  To Promote Granulosa Cell Differentiation.
reftext: Nathan C. Law, et al. Endocrinology. 2017 Jul 1;158(7):2043-2051.
pmc_ranked_result_index: '160344'
pathway_score: 0.9605213
filename: en.2017-00163f3.jpg
figtitle: Modeled mechanism by which FSH via PKA inhibits MKP3/DUSP6 to promote the
  accumulation of phosphorylated ERK in preantral GCs
year: '2017'
organisms:
- Homo sapiens
ndex: a7ac35d2-ded6-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5505220__en.2017-00163f3.html
  '@type': Dataset
  description: Modeled mechanism by which FSH via PKA inhibits MKP3/DUSP6 to promote
    the accumulation of phosphorylated ERK in preantral GCs. Schematic model, based
    on recent publications (, ), reflects the observation that the EGFR pathway is
    constitutively active in the absence of FSH, such that MEK phosphorylation is
    abrogated by the EGFR antagonist AG1478, the Src homology 2–domain-containing
    tyrosine phosphatase-2 inhibitor NSC87877, a dominant negative (S17N) RAS, and
    the MEK inhibitor PD98059. FSH promotes an accumulation of phosphorylated ERK,
    in a PKA-dependent manner, without affecting MEK phosphorylation. ERK is dephosphorylated
    in the absence of FSH by MKP3/DUSP6; FSH in a PKA-dependent manner inhibits this
    phosphatase to allow the accumulation of MEK-phosphorylated ERK that then signals
    to ribosomal S6 kinase-2 and Y-box-binding protein 1. Dotted line indicates that
    the mechanism by which PKA inhibits MKP3/DUSP6 is not known.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - FSHB
  - EGFR
  - PKIA
  - CGA
  - DUSP6
  - PKIG
  - FSHR
  - PKIB
  - GRB2
  - SOS2
  - PRKAR2B
  - PTPN11
  - SOS1
  - PRKAR1B
  - PRKAR2A
  - PRKACA
  - RAF1
  - PRKACG
  - BRAF
  - PRKAR1A
  - NRAS
  - HRAS
  - KRAS
  - ARAF
  - PRKACB
  - JEPD98059
  - Cancer
  - Noonan syndrome
genes:
- word: FSH
  symbol: FSH
  source: bioentities_symbol
  hgnc_symbol: FSHB
  entrez: '2488'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: PKI
  symbol: PKI
  source: bioentities_symbol
  hgnc_symbol: PKIA
  entrez: '5569'
- word: FSH
  symbol: FSH
  source: bioentities_symbol
  hgnc_symbol: CGA
  entrez: '1081'
- word: DUSP6
  symbol: DUSP6
  source: hgnc_symbol
  hgnc_symbol: DUSP6
  entrez: '1848'
- word: PKI
  symbol: PKI
  source: bioentities_symbol
  hgnc_symbol: PKIG
  entrez: '11142'
- word: FSHR
  symbol: FSHR
  source: hgnc_symbol
  hgnc_symbol: FSHR
  entrez: '2492'
- word: PKI
  symbol: PKI
  source: bioentities_symbol
  hgnc_symbol: PKIB
  entrez: '5570'
- word: GRB2
  symbol: GRB2
  source: hgnc_symbol
  hgnc_symbol: GRB2
  entrez: '2885'
- word: SoS
  symbol: SOS
  source: bioentities_symbol
  hgnc_symbol: SOS2
  entrez: '6655'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR2B
  entrez: '5577'
- word: SHP2
  symbol: SHP-2
  source: hgnc_alias_symbol
  hgnc_symbol: PTPN11
  entrez: '5781'
- word: SoS
  symbol: SOS
  source: bioentities_symbol
  hgnc_symbol: SOS1
  entrez: '6654'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR1B
  entrez: '5575'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR2A
  entrez: '5576'
- word: MKP3/
  symbol: MKP-3
  source: hgnc_alias_symbol
  hgnc_symbol: DUSP6
  entrez: '1848'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKACA
  entrez: '5566'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKACG
  entrez: '5568'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR1A
  entrez: '5573'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKACB
  entrez: '5567'
chemicals:
- word: JEPD98059
  source: MESH
  identifier: C093973
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
figid_alias: PMC5505220__F3
redirect_from: /figures/PMC5505220__F3
figtype: Figure
---
